Letter to the Editor

Early B cell developmental impairment with progressive B cell deficiency in NFKB2 mutated CVID disease without autoimmunity

ARTICLE INFO

Keywords:
NFKB2
B cells
Bone marrow
Autoimmunity
CVID

ABSTRACT

This study provides evidence for a novel role for NFKB2 in human B cell development in the bone marrow and in the periphery, leading to progressive peripheral B cell deficiency not always combined with autoimmune phenomena, broadening thus the clinical spectrum of NFKB2 mutated CVID disease and implying an essential role for NFKB2 in early human B cell development.

To The Editor:

NFKB2 is the cornerstone of the non-canonical NF-kB pathway, which has been shown to be critical for the development of secondary lymphoid organs, B cell development, and the humoral response to T-dependent and T-independent antigens [1,2]. Monoallelic loss-of-function mutations in NFKB2 were identified in a limited number of patients with a CVID-like disease characterized by early-onset infections, hypogammaglobulinemia, variable B cell lymphopenia, and impaired terminal B cell development [4–8]. Additional features of this disease found in some, but not all patients, include reduced NK cell numbers, ACTH deficiency, alopecia, and trachyonychia [3]. In contrast, two heterogeneous gain of function mutations in NFKB2 leading to nuclear retention and constitutive NF-kB activation have been associated with a combined immunodeficiency characterized by B cell lymphopenia and variable T cell lymphopenia [8]. While peripheral B cell lymphopenia has been reported in patients with NFKB2 mutations [4,5,7,8], early B cell development has not been previously studied in these patients. We present a patient with a frameshift mutation in NFKB2 and document an early B cell developmental impairment in the bone marrow with progressive peripheral B cell deficiency.

The index patient is the son of non-consanguineous Italian parents. He had a history of recurrent upper respiratory tract infections and measles complicated by pneumonia that required hospitalization at the age of 5 years. He was initially treated at an outside medical center and came to our attention at 14 years of age. His immunologic evaluation revealed an early B cell developmental arrest at the CD34⁺CD22⁺CD19⁺CD10hiCD45lo pre-BI stage (Fig. 1B), similar to that found in a patient with Igδ deficiency (Fig. 1C). Next-generation sequencing of 264 genes associated with primary immunodeficiency identified a heterozygous mutation NFKB2 (c.2257C > T; p.Arg853*) (Fig. 1D). This mutation, which has been previously reported, inhibits p100 processing and nuclear translocation of p52 [3]. Compared to previously published patients with this mutation, our proband, who is currently 40 years old, has had no manifestations of autoimmune disease (Supplemental Table 2).

The role of NFKB2 in B cell development has been mainly studied in mice [2,9]. NFKB2 knock-out mice showed a reduction in the B cell compartment both in the spleen and in the bone marrow, which was not apoptosis-related [2]. T-dependent and-independent immune responses were severely compromised in the knock-out animal model, with associated impaired germinal center formation [2]. The index patient had a block at the pre-BI stage, indicating an important role for NFKB2 in human early B cell development, as suggested by the animal models [2,9], associated with a progressive reduction in peripheral transitional B cells (Supplemental Table 3).

Monoallelic NFKB2 mutations have been associated with variable clinical presentation in a small subset of patients with primary immunodeficiencies [2–8]. The p.Arg853* mutation has been reported in 9 patients so far [6] (Supplemental Table 2). Patients with this mutation have most of the originally described features of the disease: hypogammaglobulinemia, respiratory infections, ACTH deficiency, hypothyroiditis, alopecia universalis, and skin disease (Supplemental Table 2). Of note, the index patient presented with hypogammaglobulinemia and only mild respiratory infections [6] (Supplemental Table 2), suggesting that the same NFKB2 mutation may give rise to a wide spectrum of clinical presentation.

Taken together, our data provide evidence for a novel role for NFKB2 in early human B cell development. In addition, our data suggest that the clinical presentation of patients carrying the same NFKB2 mutation (p.Arg853*) can be variable, with even absence of major hallmarks of the disease, and thus, next generation sequencing techniques may be helpful in identifying affected patients.

Supplementary data to this article can be found online at
Acknowledgments

We would like to thank the patients, the patients’ families and the nurses for all their efforts. We thank Raif S. Geha, Janet Chou, and the members of their laboratories for providing the next-generation DNA sequencing data and for their discussions of this work.

Funding

The research leading to these results has received funding from the European Community’s Seventh Framework Programme FP7/2007–2013 under grant agreement no 201549 (EURO-PADnet HEALTH-F2–2008-201549) and from the Italian Ministerial Grant GR-2010-2315762. The research leading to these results also received funding from the “Fondazione C. Golgi”, Brescia, Italy and the Jeffrey Modell Foundation.

Disclosure of conflicts of interest

The authors declare no conflict of interest.

References

Letter to the Editor

Vassilios Lougarisa⁎, Daniele Morattob, Manuela Baronioa, Tiziana Lorenzini, Stefano Rossia, Luisa Gazzurellia, Maria Pia Bondionia, Alessandro Plebania

a Pediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, University of Brescia, Spedali Civili di Brescia, Italy
b Institute for Molecular Medicine A. Nocivelli, Department of Pathology, Laboratory of Genetic Disorders of Childhood, Department of Molecular and Translational Medicine, University of Brescia, Spedali Civili di Brescia, Italy
c Pediatric Radiology, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy

⁎ Corresponding author: Pediatrics Clinic and Institute of Molecular Medicine “A. Nocivelli”, Department of Clinical and Experimental Sciences, University of Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy.

E-mail address: vlougarisbs@yahoo.com (V. Lougaris).